Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single ascending dose study of IV and IM GM-2505 in healthy volunteers
NL-OMON56273Recruiting
- Sponsor
- Gilgamesh Pharmaceuticals
- Start
- Nov 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of bretisilocin in major depressive disorder (MDD) (4 arms), sponsored by Gilgamesh Pharmaceuticals. Primary endpoints: Adverse events, Hematology and 8 more. Started Nov 2022; status: recruiting.
02
Drugs
bretisilocin
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NL-OMON56273.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56273.